Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.

Forty patients with advanced breast cancer, randomised to receive CMF or weekly low dose Epirubicin, were evaluated by UICC criteria of response and WHO toxicity criteria, in addition to three QoL instruments: the 'Qualitator' daily diary card, 4 weekly Nottingham Health Profile (NHP) and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fraser, S. C., Dobbs, H. J., Ebbs, S. R., Fallowfield, L. J., Bates, T., Baum, M.
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1968186/
https://ncbi.nlm.nih.gov/pubmed/8431375
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares